On March 8th, Tommy Sopko pitched Merck (NYSE: MRK), a global healthcare company that develops medicines, vaccines, biologic therapies, and animal health solutions. Merck operates in two major segments: pharmaceuticals and animal health. Their largest area for growth is oncology, which is also their largest segment by revenue. Tommy discussed key risks and mitigants including a dependency on patent rights, international business, and successful R&D initiatives. The class approved the pitch and voted to buy 400 shares of MRK, sell 125 shares of ZTS, and sell 200 shares of EW.